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ABSTRACT
VEGF (vascular endothelial growth factor) prevents neuronal
death in different models of ALS (amyotrophic lateral
sclerosis), but few studies have addressed the efficacy
of VEGF to protect motor neurons after the onset of symp-
toms, a critical point when considering VEGF as a potential
therapeutic target for ALS.We studied the capability of VEGF
to protect motor neurons after an excitotoxic challenge in
two models of spinal neurodegeneration in rats induced by
AMPA (a-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid) administered either chronically with osmotic mini-
pumps or acutely by microdialysis. VEGF was administered
throughosmoticminipumpsinthechronic modelorinjected
intracerebroventricularly in the acute model, and its effects
were assessed by immunohistochemical and histological
analyses and motor performance tests. In the chronic model,
VEGF stopped the progression of the paralysis and protected
motor neurons when administered after AMPA before the
onset of the motor symptoms, whereas no protection was
observed when administered after the onset. VEGF was also
protective in the acute model, but with a short time window,
since the protection was effective when administered 1 h
but not 2 h after AMPA. Our results indicate that while VEGF
has an indubitable neuroprotective effect, its therapeutic
potential for halting or delaying the progression of motor
neuron loss in ALS would likely have a short effective time
frame.
Key words: amyotrophic lateral sclerosis, neurodegenera-
tion, neuroprotection, spinal cord, rat.
INTRODUCTION
ALS (amyotrophic lateral sclerosis) is the most common type
of motor neuron disease and is characterized by the selective
and progressive loss of motor neurons in the spinal cord,
brainstem and motor cortex, with the first symptoms
occurring in mid-adult life. Depending on its origin ALS is
categorized into two types, FALS (familial ALS) or SALS
(sporadic ALS), the latter accounting for ,90% of the cases.
ALS is a multi-factorial and non-cell autonomous disease (see
Ilieva et al., 2009, for a review). The molecular and cellular
processes that cause the loss of motor neurons still need to be
clarified, but, regardless of the mechanism of neuronal death,
VEGF (vascular endothelial growth factor) has been consis-
tently shown to be an effective protector against motor
neuron loss under different experimental paradigms, both in
vitro (Li et al., 2003; Van Den Bosch et al., 2004; Tolosa et al.,
2008) and more importantly, in vivo. Several studies have
proven that VEGF protects motor neurons from mutant
SOD1 (superoxide dismutase 1)-induced neuronal loss
(Azzouz et al., 2004; Zheng et al., 2004; Storkebaum et al.,
2005; Lunn et al., 2009), and we have demonstrated that
VEGF is also effective against motor neuron degeneration
induced by excitotoxicity (Tovar-y-Romo et al., 2007)
through a mechanism that involves the direct activation of
VEGFR2 (VEGF receptor 2) expressed in these neurons (Tovar-
y-Romo and Tapia, 2010). Interestingly, the expression of this
receptor is diminished in ALS surviving motor neurons
(Brockington et al., 2006; Lunn et al., 2009).
In most of the studies with experimental paradigms in vivo
VEGF has been administered prior to any noticeable motor
deficits. Nevertheless, in the majority of SALS cases and given
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asnneuro.org / Volume 4 (2) / art:e00081 121the lack of reliable biomarkers (Pradat and Dib, 2009) is
unfeasible to predict who will develop the disease at a later
stage in life, so that an early preventive treatment starting
before the onset would be practically futile. Therefore, it is
indispensable to assay the efficacy of VEGF or any other
intended therapeutic agent, under experimental conditions in
which the motor neuron death process start before the
administration of the neuroprotective agent, in order to
assess its effectiveness for stopping such a neurodegenerative
process.
In this work, we administered VEGF to adult rats after they
were infused with the glutamate receptor agonist AMPA (a-
amino-3-hydroxy-5-methylisoxazole-4-propionic acid) in the
spinal cord, either chronically or acutely, in two experimental
models of excitotoxic spinal neurodegeneration that we
previously reported to cause hind limb paralysis due to the
loss of lumbar motor neurons (Corona and Tapia, 2004; Tovar-
y-Romo et al., 2007). While the controversy on the role that
excitotoxicity plays in the actual human disease still goes on
(Corona et al., 2007; Tovar-y-Romo et al., 2009b; Bogaert
et al., 2010), this mechanism provides a means by which we
can assay the neuroprotective properties of VEGF in vivo and
correlate the motor performance with the histopathology of
the spinal cord.
MATERIALS AND METHODS
Animals
Adult male Wistar rats (270–290 g) were used in all the
experiments. Procedures were performed in accordance with
the Rules for Research in Health Matters (Mexico), with the
approval of the local Animal Care Committee (Office of
Laboratory Animal Welfare ID number A5281-01). Animals
were housed in a laboratory environment with a 12 h light/
12 h dark cycle and with food and water ad libitum. All
surgical procedures were performed under anaesthesia, and
all efforts were made to minimize suffering during the
experimental procedures.
Surgical implantation of the osmotic minipumps
The implantation of osmotic minipumps was carried out as
previously described (Tovar-y-Romo and Tapia, 2010), slightly
modified toallow the connection of a second osmoticminipump
to the same infusion cannula at a later time point. Briefly, rats
were anaesthetized with 5% isoflurane in a 95% O2/5% CO2
mixture and placed in a stereotaxic spinal unit. Anaesthesia was
lowered and maintained at 1–2% isoflurane during surgery. A
longitudinal incision of the back skin was made at the lumbar
region and muscles surrounding lumbar vertebrae were cut and
retracted. On the second lumbar vertebra, the spinous process
was removed and an ,1-mm-diameter hole was drilled on the
left side of the lamina in which a stainless-steel screw (1 mm
diameter; 3.7 mm long) was inserted to anchor the implant. An
,2m m
2 laminectomy was made in the right side of the lamina
of the same vertebra and a small cut of the meninges was made
to insert into the dorsal parenchyma (,1 mm deep) the tip of a
double concentric cannula (CMA/7 Stockholm, Sweden) from
whichthedialysismembranewasremovedbycutting theendof
the shaft. Thus, this modified infusion cannula has two inlet
tubes, and one of them was sealed at the moment of
implantation. Dental cement was poured over the screw and
the plastic support of the cannula and the open inlet was
connected to an osmotic minipump (Alzet, model 2004,
approximate capacity 200 ml, flow rate 0.25 ml/h; Durec)
containing a solution of 7.5 mM AMPA (Tocris) in 0.1 M PB
(phosphate buffer), pH 7.4. This concentration of AMPA has
beenshownbeforetobethemostconvenientforthepurposeof
the experiment (Tovar-y-Romo et al., 2007). The pump was
implanted subcutaneously in the back of the rat, the skin
incision was closed with surgical stainless-steel clips and rats
received an intramuscular dose of penicillin.
The second minipump was connected at a later time point
(see the Results section), but not less than 24 h after the first
implant surgery. For this, rats were anaesthetized with
isoflurane and placed in a stereotaxic frame as described
above. The surgical clips were removed, the previous incision
was gently pulled apart to expose the implanted cannula, and
the tip of its free sealed end was cut and connected to a
minipump containing recombinant rat VEGF164 (Sigma)
dissolved in 0.1 M PB at a concentration calculated to deliver
24 ng/day (Tovar-y-Romo et al., 2007). The pump was placed
subcutaneously and the skin incision was again closed with
surgical stainless-steel clips.
Pumps were filled at least 40 h before the implantation
and incubated in sterile saline at 37˚C for stabilization.
Spinal cord microdialysis
Microdialysis administration of AMPA in the rat spinal cord
was performed as previously described (Corona and Tapia,
2004). Briefly, rats were anaesthetized with isoflurane and
placed in a stereotaxic spinal unit as described above. Animals
were maintained under low anaesthesia (1–2% isoflurane)
throughout the experiment. Lumbar vertebrae were exposed
as described above and a ,2 mm hole was drilled on the
right side of the lamina on L2. Then, after carefully cutting
the meninges an intact microdialysis probe (CMA/7) was
lowered down into the right dorsal horn of the spinal cord.
The probes were continuously perfused with a Krebs–Ringer
solution (118 mM NaCl, 4.5 mM KCl, 2.5 mM MgSO4, 4.0 mM
NaH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3 and 10 mM gluc-
ose, pH 7.4), at a flux rate of 2 ml/min. AMPA was
administered by perfusing for 25 min a 6 mM solution
prepared in Krebs–Ringer medium in which osmolarity was
maintained by reducing the NaCl concentration proportion-
ally. This AMPA concentration was chosen on the basis of
previous results (Corona and Tapia, 2004). At the end of the
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the skin incision was closed with surgical clips.
i.c.v. (intracerebroventricular) administration of
growth factors
In the acute model of AMPA by microdialysis, VEGF or
recombinant human BDNF (brain-derived neurotrophic fac-
tor; Sigma) were microinjected intracerebroventricularly
30 min before or at 1 or 2 h after AMPA perfusion, using
the following stereotaxic co-ordinates: AP 20.5 mm from
Bregma, L +1.5 mm from mid-line, V 24 mm from skull
surface. Control rats received a 5 ml volume of Krebs–Ringer
medium. The experimental groups were injected with 50 ng
of recombinant VEGF in a 5 ml volume or 30 ng of BDNF in a
3ml volume, with a flux rate of 1 ml/min (concentrations
of VEGF and BDNF are closely equimolar).
Assessment of motor function in the chronic
model of spinal neurodegeneration
Motor performance was evaluated as described previously
(Tovar-y-Romo et al., 2007). Rats were trained for 2 days prior
to the surgery on two motor tests: a variation of the PGE
(paw grip endurance) task and the rotarod (Columbus
Instruments). Animals were evaluated in each test routinely
until fixation. For the PGE test, rats were placed individually
on a horizontally placed grid (30619 cm) attached to a
mechanical rotator. The grid was gently turned (3 rev./min)
until reaching a vertical position. The time taken by the rats
for climbing to the top of the grid and reaching a stable
position or the latency to fall from the grid when they were
unable to climb was scored with a cut-off of 40 s. For the
rotarod test, rats walked individually on an accelerating
(0.2 rev./min per s) rod, starting from 10 rev./min with a cut-
off of 120 s, and the time on the rod was scored. In addition
to the motor tests, the overall stride pattern of the hind
footprints was qualitatively analysed; for this purpose, the
hindpaws of treated rats were inked with non-toxic Chinese
ink before animals walked along a paper runway.
Histology and immunohistochemistry
For histological and immunohistochemical analyses, the rats
implanted with osmotic minipumps were fixed when they
reached the lowest scores on the motor tests or at 20 days
after implantation when they did not score low, and the rats
subjected to spinal cord microdialysis were fixed 24 h after
AMPA perfusion. For fixation, animals were anaesthetized
with barbiturate and perfused transcardially with 250 ml of
ice-cold 0.9% saline, followed by 250 ml of ice-cold 4%
paraformaldehyde in PB, pH 7.4. Spinal cords were removed,
postfixed at 4˚C and successively transferred to sucrose
solutions (up to 30%). Transverse 40 mm sections of the
lumbar region, where the infusion or microdialysis cannula
was implanted, were obtained in a cryostat. Alternate sections
were stained with Cresyl Violet or immunostained for ChAT
(choline acetyltransferase) and GFAP (glial fibrillary acidic
protein). Free-floating sections were blocked with 5% BSA in
PBS–Triton X-100 (0.3%) for 2 h, and then incubated with
goat polyclonal anti-ChAT (1:200, Chemicon) and rabbit anti-
GFAP antibodies (1:1000; Sigma), for 48 h at 4˚C. Sections
were washed 3610 min in PBS–Triton X-100 and incubated
with biotin-conjugated mouse anti-goat IgG (1:200, Vector)
for 1 h. After three washes, sections were incubated for 2 h
with avidin-Texas Red conjugate (1:200, pH 8.2, Vector) and
fluorescein-conjugated anti-rabbit antibody (1:250 Zymed)
for 2 h. Finally, sections were washed and mounted on silane
(c-methacryloxypropyltrimethoxysilane; Sigma)-covered
slides and coverslipped with fluorescent mounting medium
(DAKO). Sections were visualized under confocal microscopy
(Olympus IX81); merged images are the overlay of two laser
sections in the Z-plane, using the Olympus Fluoview 1.6
Viewer. Morphologically undamaged motor neurons in the
Nissl preparations (with a soma diameter .25 mm and a
distinguishable nucleus) were counted in a 610 microscopic
field. The number of cells was determined in sections where
the trace of the cannula (infusion or microdialysis) was
evident; five sections per rat were analysed and the values
were averaged.
Statistical analysis
Comparisons regarding number of motor neurons were made
using ANOVA followed by a Fisher’s post-hoc test. P,0.05
was considered statistically significant.
RESULTS
Chronic administration of VEGF after AMPA but
before the onset of symptoms rescues motor
neurons and prevents the progression of
paralysis
Chronic delivery of AMPA in the rat lumbar spinal cord, by
means of osmotic minipumps, causes a progressive paralysis
of the rear limbs (Tovar-y-Romo et al., 2007). The first
symptoms of motor impairment are characterized mainly as
an ipsilateral limping that becomes evident after 24 h of sur-
gery. The limping progresses to a state of rigid flexion of
the ipsilateral limb by days 2–3 after surgery and at this
time motor deficits begin to appear in the contralateral limb.
The motor dysfunction progresses to a state of complete
bilateral paralysis over a period of 20 days. However, by day
10 the paralysis, although not complete, is clearly evident, as
rats perform poorly in the rotarod and even though they are
still able to climb on the PGE test, the scores are significantly
lower than baseline. In previous work, we have shown that
VEGF protects against motor neuron death
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123control rats infused only with vehicles (Krebs–Ringer medium
or DMSO) or VEGF alone do not develop any motor alteration
at any time (Tovar-y-Romo et al., 2007; Tovar-y-Romo and
Tapia, 2010).
We administered 24 ng/day of recombinant VEGF via a
second osmotic minipump, to rats previously implanted with
an AMPA-filled pump, before and after the time they showed
a clear ipsilateral limp. This time was variable, occurring
between days 2 and 4 after the implantation of AMPA
minipump, so that the pre-symptom administration of VEGF
through the second minipump started 24–36 h afterwards
and the post-symptom administration started at 2–4 days.
None of the rats of the post-symptom administration group
(n58) was protected and all animals showed irreversible and
progressive motor impairments reaching bilateral paralysis, as
described above for animals receiving only AMPA. This was
reflected by a continuous decrease in rotarod and PGE scores
(Figure 1). In contrast, all the animals receiving VEGF before
the appearance of the ipsilateral limping (n56) displayed
only a transitory decrease in both rotarod and PGE scores that
did not progress to a permanent paralytic state. Even more,
all the rats recovered a normal motor performance by day 7
after AMPA administration (6 days of VEGF treatment)
(Figure 1). In this group, the ipsilateral limp remained but
did not progress to the rigid flexion seen in the non-
protected rats (see footprints in Figure 1).
As expected, the rats treated with VEGF after the onset of
symptoms showed a remarkable loss of motor neurons, which
correlated with their paralytic state, as well as an intense
astrocytic inflammatory response detected by GFAP immu-
nolabelling (Figure 2), similar to the changes observed after
the infusion of AMPA alone (Tovar-y-Romo et al., 2007).
In contrast, the early administration of VEGF before the
symptoms clearly prevented neuronal death and astrogliosis.
As shown in Figure 2, in these rats most of the motor neurons
are preserved in the ipsilateral side of the spinal cord and no
neurodegeneration whatsoever occurred in the contralateral
side that shows the same baseline number of motor neurons
as in rats treated with Krebs–Ringer medium, with DMSO or
with VEGF alone (results not shown; see Tovar-y-Romo et al.,
2007; Tovar-y-Romo and Tapia, 2010). Notably, the number
of neurons protected by VEGF, both in the ipsilateral and
contralateral sides, is remarkably similar to the number of
healthy motor neurons preserved when VEGF is co-adminis-
tered together with AMPA (Tovar-y-Romo et al., 2007).
i.c.v. injection of VEGF protects motor neurons
against AMPA-induced acute excitotoxicity
In order to test whether a systemic (i.e. non-local)
administration of VEGF could also be protective, a single
dose of VEGF (50 ng) was injected in the lateral cerebral
ventricle in the acute model of spinal neurodegeneration.
Microdialysis perfusion of AMPA in the lumbar spinal cord,
but no Krebs–Ringer, L-2,4-trans-pyrrolidine dicarboxylate,
leupeptin or NMDA perfusion, causes a rapid, irreversible and
complete paralysis of the ipsilateral limb that develops over
the course of 6–12 h, due to an almost complete progressive
Figure 1 Chronic administration of VEGF after AMPA but before the onset of symptoms prevents the progression of paralysis
Top panels: time course of rotarod and PGE performances of rats infused with AMPA that received VEGF before (closed circles, n56)
or after (open squares, n58) the initial symptoms of motor impairment. Each point in the graphs is the means¡S.E.M. of the best
score out of three trials obtained by each rat at the time points tested. Bottom panel: representative footprints of rats treated with
AMPA followed by VEGF before and after the initial motor disturbances. Notice the progression of paralysis in the rat treated after
the initial symptoms, observed by a continuous mark left by the dragging of hindlimbs, whereas the rat treated before the symptoms
presented only an ipsilateral limp depicted as a shrunken footprint (right footprint on top of the lane). N.D., not determined.
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2008). We found that control rats that received Krebs–Ringer
medium i.c.v. 30 min before AMPA infusion displayed the
previously observed progression of motor deficits, reaching
complete paralysis of the ipsilateral limb at approx. 12 h, and
showed a near 90% motor neuron loss in the perfused side
of the spinal cord 24 h after surgery (n54) (Figure 3). In
contrast, the rats that received VEGF i.c.v. 30 min before
AMPA were remarkably protected from paralysis, as no motor
impairments occurred during the following 24 h and,
accordingly, neuronal death was almost totally prevented
(n58) (Figure 3).
To test if this protection was specifically mediated by VEGF,
we assayed the administration of a closely equimolar dose of
BDNF (brain-derived neurotrophic factor; 30 ng) under the
same experimental conditions. BDNF 30 min before AMPA did
not exert any protective effect on motor neuron survival.
These animals also showed progressive motor deficits reach-
ing complete paralysis of the ipsilateral hindlimb and most
motor neurons were lost at 24 h, similar to control rats
receiving i.c.v. Krebs–Ringer medium (n58) (Figure 3).
Then, we explored whether a delayed i.c.v. administration
of VEGF could still be protective. When VEGF was injected 1 h
after the spinal perfusion of AMPA there was a remarkable
preservation of the motor neurons in the perfused side of the
spinal cord. Although there was a significant decrease of
,25% in the number of motor neurons as compared with the
group treated with VEGF 30 min before AMPA (P50.022), the
healthy motor neurons remaining at 24 h were sufficient to
maintain normal motor function, since no overt motor
deficits were observed in any of the rats and the ipsilateral
hindlimb paralysis did not occur (n58). However, when VEGF
was injected i.c.v. 2 h after AMPA, in spite of a slightly
significant protection regarding the number of healthy motor
neurons as compared with the control group treated with
Krebs medium (P50.038), there was a ,75% motor neuron
loss after 24 h (n59, Figure 3) and all the rats developed
hindlimb palsy, similar to the i.c.v. Krebs–Ringer control rats.
DISCUSSION
In the present work, we demonstrate that the intraspinal
or i.c.v. administration of VEGF after the initiation of a
neurodegenerative process generated by a chronic or acute
excitotoxic stimulus prevents the degeneration and death of
spinal motor neurons, although within a brief time window.
This indicates that the potential of VEGF for protection rapidly
decreases once the neurodegeneration process has surpassed a
threshold of spinal motor neuron damage.
Despite the accumulating studies on the molecular and
cellular mechanisms that cause motor neuron death in ALS,
the precise processes underlying the disease in humans are
still not fully elucidated. There is a considerable amount of
evidence indicating that toxic Ca
2+-dependent processes such
as excitotoxicity, mitochondrial dysfunction, endoplasmic
reticulum stress and oxidative stress, as well as other
processes not necessarily dependent on Ca
2+ deregulation,
like protein misfolding and aggregation, axonal transport
impairment and inflammation, may play a role in the
pathogenesis (Grosskreutz et al., 2010). From the studies in
the transgenic models of FALS that harbour mutant forms of
SOD1 we know that all these alterations may occur in motor
neurons and their neighbour cells, and the fact that VEGF
delays the onset of symptoms, retards the paralysis
progression and therefore extends the survival in these
animals, indicates that VEGF can significantly hinder at least
some of the toxicity resulting from these events. Nonetheless,
the mutant SOD1 transgenic experimental models only
reproduce the mechanism of death that happens in less than
3% of ALS cases (Tovar-y-Romo et al., 2009a).
We previously demonstrated that when administered
together with AMPA, VEGF completely prevents the spinal
neurodegeneration elicited by AMPA-induced excitotoxicity
(Tovar-y-Romo et al., 2007) and that this protection is
Figure 2 Chronic administration of VEGF after AMPA but before the onset
of symptoms rescues motor neurons from death
Representative micrographs of the ventral horns immunostained for ChAT
(red) and GFAP (green) in the lumbar section of spinal cord of rats treated
with AMPA followed by VEGF before or after the initial symptoms of paralysis.
Note the remarkable loss of motor neurons and the intense glial reac-
tion induced by AMPA in both sides of the spinal cord in the rat treated with
VEGF after the symptoms onset and the protection exerted by VEGF when
infused after AMPA but before the onset. Scale bar5100 mm. The graph
shows the number of healthy motor neurons counted on the Nissl staining.
Values are means¡S.E.M. (five slices per rat, n56 in the group treated with
VEGF before and n58 in the group treated after the initial symptoms).
*P,0.0001 as compared with corresponding side in the opposite group.
#P,0.0001 as compared with the contralateral side in the same
group (ANOVA followed by Fisher’s post-hoc test).
VEGF protects against motor neuron death
E 2012 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
125achieved by the activation of VEGFR2 and the downstream
activation of the survival signalling pathway PI3K (phosphoi-
nositide 3-kinase) and the inhibition of p38 (Tovar-y-Romo
and Tapia, 2010). This indicates that the trophic support of
VEGF is protective in spite of the toxic processes to which
motor neurons are subjected, even when they are not due to
mutations in SOD1 or any other altered gene. In fact, this
trophic factor is required for the normal function of motor
neurons, as demonstrated by the paralysis that mice with a
deleted hypoxia response element in the promoter of the Vegf
gene develop due to the loss of spinal motor neurons
(Oosthuyse et al., 2001).
The experimental models that were used in this study are
based on the toxicity elicited by the over-activation of AMPA
receptors, in accordance to one of the main hypotheses on
the neuronal death in ALS (Corona and Tapia, 2007). As
mentioned before, these models offer the advantage of
evaluating the protective effects of VEGF on motor neurons
that do not bear genetic alterations, which is the most
common scenario in the actual human SALS disease. The
Figure 3 i.c.v. injection of VEGF shortly after AMPA microdialysis perfusion protects motor neurons against death and prevents paralysis
Representative micrographs of the ventral horns immunostained for ChAT (red) and GFAP (green) in the lumbar section of spinal cord
of rats perfused with AMPA by means of microdialysis and injected i.c.v. with Krebs–Ringer medium 30 min before AMPA (n54),
BDNF 30 min before AMPA (n58) and VEGF 30 min before AMPA (n58) or at 1 h (n59) or 2 h (n59) after AMPA. Note the loss of
motor neurons in the ipsilateral side of the control groups treated with Krebs or with BDNF and the remarkable protection induced by
VEGF injected 30 min before AMPA. At 1 h this protection is still present, although significantly reduced, while at 2 h it is almost
completely lost. Scale bar5100 mm. The graph shows the number of healthy motor neurons counted on the Nissl staining. Values are
means¡S.E.M. (five slices per rat). *P,0.0001 as compared with the corresponding side in the group treated with Krebs. #P,0.0005
as compared with the corresponding side in the group treated with VEGF 30 min before AMPA (ANOVA followed by Fisher’s post-hoc
test).
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neuron death in the genetic rodent models of ALS, specifically
those with mutations in SOD1, are not fully understood, and
while excitotoxicity has been considered to be involved, there
is not a definitive demonstration that this actually occurs
(Tovar-y-Romo and Tapia, 2006; Tovar-y-Romo et al., 2009a).
Nonetheless, the fact that VEGF rescues motor neurons from
death elicited either by genetic mutations or by excitotoxicity
may predict the existence of intersecting points in these two
types of neuronal injury. Targeting these common pathways
may be a useful approach to understand the basic biological
alterations that occur in motor neurons.
As we demonstrate here, while VEGF can clearly protect
motor neurons from AMPA-mediated excitotoxicity, it has a
short-time frame for protection once the noxious process is
triggered in the neurons. In the chronic model, the beginning
of the neuronal death process does not result in any obvious
symptom of paralysis, such as limping, but it can be measured
with the aid of motor tests, as shown by the decline in both
rotarod and PGE scores of the rats treated with VEGF after
AMPA but before the onset of symptoms. This decline,
however, is not due to the loss of motor neurons, as shown by
the histological analysis of the protected rats. In this sense, it
is noteworthy that the transgenic models of FALS, bearing
human (Dal Canto and Gurney, 1995; Bruijn et al., 1997) or
murine (Morrison et al., 1998) mutant SOD1 do not present a
significant loss of motor neurons prior to the onset of
symptoms, and the time course of neuronal loss occurs at a
very fast rate over a period of 10 days (Morrison et al., 1998).
Notably, in human histological studies of spinal cord there is
a large variability between the degree of motor neuron loss
and muscle weakness (Stephens et al., 2006). This could mean
that a very early intervention with growth factors could still
be effective. In fact, in the FALS models the administration of
VEGF (Azzouz et al., 2004; Storkebaum et al., 2005) or IGF-1
(insulin-like growth factor 1; Kaspar et al., 2003; Dodge et al.,
2008) at the onset of symptoms delays the progression
and increases lifespan, although the administration of these
growth factors well before the onset confers a significant
better protection. This difference possibly means that VEGF is
helpful at preventing the accumulating toxicity that arises
from neurodegenerative processes that begin before motor
neuron death or symptom onset (Dal Canto and Gurney,
1995; Bendotti et al., 2001).
In the acute model, we previously found that although the
neuronal death occurs fairly quickly, over the course of 6–
12 h, the first histological alterations appear as soon as 3 h
after microdialysis delivery of AMPA (Corona and Tapia,
2008). In the present work, we found that when the i.c.v.
administration of VEGF is delayed 1 h after AMPA, VEGF is
still capable of rescuing the majority of motor neurons and
therefore prevent the ipsilateral paralysis. However, this
protective effect is significantly hampered when VEGF is
given 2 h after AMPA. We have consistently found in our
experimental settings that there is a threshold that motor
neuron death must overpass in order to be reflected as
motor impairments and paralysis. Experimental data from our
laboratory show that energetic metabolites or antioxidant
agents that rescue at least half the motor neurons in the
lumbar spinal cord from AMPA-induced excitotoxic death
also prevent the ipsilateral hind limb paralysis that follows
AMPA administration, whereas drugs that rescue less than
half motor neurons do not prevent motor impairments
(Corona and Tapia, 2007, 2008; LD Santa-Cruz and R Tapia,
unpublished data).
The i.c.v. administration of VEGF has also been proven
efficient in the rat transgenic model of FALS (Storkebaum
et al., 2005). Opposite to the local administration in the spinal
cord achieved by the continuous infusion of VEGF in the
chronic model, the i.c.v. administration allows the diffusion
of the growth factor throughout the entire spinal cord,
although this administration way must probably create a
concentration gradient (Storkebaum et al., 2005). This is of
special interest when considering that, in the actual human
disease, cellular alterations take place along the entire spinal
cord, which might be a target particularly difficult to reach.
Therefore, assessing different ways to deliver trophic factors
is worth trying. The continuous perfusion of trophic factors in
the spinal cord by intrathecal infusions or into the brain by
i.c.v. injections overcome the blockade that the blood–brain
barrier represents to the delivery of these molecules.
Intrathecal injections in fact have been tried in ALS patients
for the delivery of IGF-1, with modest results (Nagano et al.,
2005).
Our present results also point out at the specificity of VEGF
to protect motor neurons, since BDNF failed to do so in this
experimental model. This result is in line with previous reports
showing that BDNF was not able to protect motor neurons
from excitotoxicity (Fryer et al., 2000). Even more, BDNF may
also increase the toxicity for neurons through the activation
of NADPH oxidase (Kim et al., 2002), an enzyme that has been
shown to be involved in motor neuron pathology by
damaging the survival pathways activated by trophic factors
(Wu et al., 2006). All this could account for the failure of
BDNF in human clinical trials (The BDNF Study Group, 1999).
Because of the therapeutic success in animal models,
currently there is little doubt about the potential for
protection that VEGF has on motor neurons. However, the
majority of treatments that have been found to be effective
in experimental models do not correlate with a success in
clinical trials (Corona et al., 2007). Trophic factors are not the
exception: clinical trials assaying the protection conferred by
ciliary neurotrophic factor (ALS CNTF Treatment Study Group,
1996) and IGF-1 (Lai et al., 1997; Borasio et al., 1998) failed to
improve the condition in ALS patients even when they were
found to be protective in the transgenic rodent model (Kaspar
et al., 2003; Dodge et al., 2008). Particularly concern-
ing growth factor therapies, special attention should be given
to growth factor stability, sustained delivery and exposure,
doses, their ability to cross blood–brain barrier, the mid-life
of proteins and the unwanted side effects in non-targeted
cells (Suzuki and Svendsen, 2008). However, it is also
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127important to take into account that the moment at which
these proteins are administered can result crucial for their
therapeutic success. Unfortunately, due to the many para-
meters that have to be met in order to get a correct diagnosis
of ALS, this process is rather slow (Shook and Pioro, 2009;
Bedlack, 2010) and the earliest intervention with VEGF once a
patient is diagnosed may already be too late. Clinical trials for
VEGF are now under way to assess the safety and tolerability
of VEGF165 (Siciliano et al., 2010), and the working time frame
for VEGF therapy is an important factor that needs to be
considered regarding any clinical therapeutic success.
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